- Home
- / NGM Biopharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
NGM Biopharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.5
2024-04-05
Market Capitalization
$128.5 M
2024-04-05
Revenue
$4.4 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 77.1M | 108.7M | 103.5M | 87.4M | 77.9M | 55.3M | 4.4M |
| Revenue growth, % | 40.9% | ||||||
| General and administrative expense | 14.8M | 17.3M | 23.6M | 27.2M | 36.9M | 40.5M | 37.8M |
| Operating expense total | 94.6M | 113.0M | 152.9M | 191.2M | 221.6M | ||
| EBIT | (17.4M) | (4.3M) | (49.3M) | (103.8M) | (120.7M) | (166.2M) | (151.5M) |
| EBIT margin, % | -22.6% | -4.0% | -47.7% | -118.8% | -300.5% | ||
| Interest income | 2.4M | 3.6M | |||||
| Interest expense | 6.7M | 1.9M | 420.0K | 3.7M | 9.3M | ||
| Pre tax profit | (15.2M) | (493.0K) | (42.8M) | (102.5M) | (120.3M) | (162.7M) | (142.4M) |
| Income tax expense | (1.1M) | ||||||
| Net Income | (14.2M) | (493.0K) | (42.8M) | (102.5M) | (120.3M) | (162.7M) | (142.4M) |
| EPS | (2.0) | (1.0) |